IPN01203

**IPN01203** is an investigational biologic agent developed by Ipsen for the treatment of adults with locally advanced or metastatic solid tumors that have progressed following immune checkpoint inhibitor therapies. Administered intravenously, it is currently being evaluated in a Phase I/II first-in-human study (NCT07213830) comprising dose escalation (Phase Ia) to identify tolerable and active doses, followed by dose optimization (Phase Ib) to assess anti-tumor activity, pharmacokinetics, pharmacodynamics, immunogenicity, and safety. The study measures outcomes such as dose-limiting toxicities, objective response rate per RECIST v1.1, progression-free survival, and anti-drug antibodies, targeting patients with advanced solid tumors.[1][2][6]